Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Signs on Fifth PPO for Coverage of BrevaGen

NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement with Three Rivers Provider Network, bringing the total number of covered lives with in-network access to the company's BrevaGen breast cancer test to more than 23 million.

Three Rivers is a supplemental preferred provider organization based in Chula Vista, Calif., and provides healthcare benefits to more than 10 million members at more than 1 million sites across the country.

Today's agreement is the fifth that Melbourne, Australia-based GTG has executed with similar US PPOs, it said. Earlier this week the company reported that its third-quarter revenues narrowed 9 percent year over year. It also announced settlement deals with two companies over lawsuits alleging infringement of a patent held by GTG cover non-coding DNA technology.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.